Primary malignant mesodermal ovarian sarcomas

Int J Gynecol Cancer. 2006 Jan-Feb;16(1):106-9. doi: 10.1111/j.1525-1438.2006.00305.x.

Abstract

Primary malignant mesodermal ovarian sarcomas are rare tumors and have a poor prognosis. The disease is usually diagnosed at a late stage and 5-year survivals are uncommon. Most patients are treated with debulking surgery followed by adjuvant chemotherapy. We report ten patients treated at a single institution. All patients underwent surgery and 90% received adjuvant chemotherapy. The median survival was 20 months, and only one patient survived beyond 5 years. Newer treatment strategies are urgently needed in the management of this disease.

MeSH terms

  • Adult
  • Aged
  • Cause of Death*
  • Chemotherapy, Adjuvant
  • Cohort Studies
  • Combined Modality Therapy
  • Female
  • Humans
  • Immunohistochemistry
  • Middle Aged
  • Mixed Tumor, Mesodermal / mortality*
  • Mixed Tumor, Mesodermal / pathology*
  • Mixed Tumor, Mesodermal / therapy
  • Neoplasm Staging
  • Ovarian Neoplasms / mortality*
  • Ovarian Neoplasms / pathology*
  • Ovarian Neoplasms / therapy
  • Ovariectomy / methods
  • Prognosis
  • Risk Assessment
  • Survival Analysis
  • Time Factors